Table 2. ERβ and IGF2 status by ethnicity, age, tumor pathology and stage.
| N (%) | |||||||
|---|---|---|---|---|---|---|---|
| Total | 204 | ERβ-positive | ERβ-negative | p-Value | IGF2-Positive | IGF2-negative | P-Value |
| Ethnicity | |||||||
| African American | 50 (24.5) | 36 (72.0) | 14 (28.0) | 26 (55.3) | 21 (44.7) | ||
| Hispanic | 28 (13.7) | 18 (64.3) | 10 (35.7) | 11 (40.7) | 16 (59.3) | ||
| Asian | 126 (61.8) | 67 (53.2) | 59 (46.8) | 0.019 | 4 (3.2) | 122 (96.8) | <0.001 |
| Age (yr) | |||||||
| <50 | 90 (44.1) | 52 (57.8) | 38 (42.2) | 21 (23.9) | 67 (76.1) | ||
| ≥50 | 114 (55.9) | 69 (60.5) | 45 (39.5) | 0.774 | 20 (17.9) | 92 (82.1) | 0.378 |
| ERα/PR status | |||||||
| Positive | 130 (63.7) | 81 (62.3) | 49 (37.7) | 26 (20.3) | 102 (79.7) | ||
| Negative | 74 (36.3) | 40 (54.1) | 34 (45.9) | 0.3 | 15 (20.8) | 57 (79.2) | 1.0 |
| HER2 status | |||||||
| Positive | 52 (25.5) | 26 (50.0) | 26 (50.0) | 7 (14.0) | 43 (86.0) | ||
| Negative | 152 (74.5) | 95 (62.5) | 57 (37.5) | 0.141 | 34 (22.7) | 116 (77.3) | 0.228 |
| Subtype | |||||||
| ERα/PR+/HER2- | 104 (51.0) | 69 (66.3) | 35 (33.7) | 23 (22.3) | 80 (77.7) | ||
| HER2+ | 52 (25.5) | 26 (50.0) | 26 (50.0) | 7 (14.0) | 43 (86.0) | ||
| TNBC | 48 (23.5) | 26 (54.2) | 22 (45.8) | 0.089 | 11 (23.4) | 36 (76.6) | 0.912 |
| Tumor size | |||||||
| ≤ 2cm | 45 (22.1) | 29 (64.4) | 16 (35.6) | 12 (27.3) | 32 (72.7) | ||
| 2cm – 5cm | 115 (56.4) | 63 (54.8) | 52 (45.2) | 11 (9.7) | 102 (90.3) | ||
| > 5cm | 32 (15.7) | 23 (71.9) | 9 (28.1) | 0.677 | 14 (43.8) | 18 (56.3) | 0.208 |
| Node | |||||||
| Negative | 68 (33.3) | 44 (64.7) | 24 (35.3) | 15 (22.4) | 52 (77.6) | ||
| Positive | 127 (62.3) | 74 (58.3) | 53 (41.7) | 0.443 | 23 (18.4) | 102 (81.6) | 0.570 |
| Stage | |||||||
| 0-II | 134 (65.7) | 79 (59.0) | 55 (41.0) | 27 (20.6) | 104 (79.4) | ||
| III-IV | 66 (32.4) | 41 (62.1) | 25 (37.9) | 0.759 | 13 (19.7) | 53 (80.3) | 1.0 |